Who We Are

RadioMedix, Inc. is a clinical-stage biotechnology company, based in Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. We commercialize  radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy.

What We Do

Our operations cover the entire value chain from drug discovery to sponsoring and conducting clinical trials to scale up manufacturing. RadioMedix is compliant with 21 CFR Parts 210,211,212. Our Molecular Core Facility supports the synthesis, and the pre-clinical evaluation of our drugs and contract projects. Our cGMP Suite manufactures doses for  Phase I-III clinical trials. Our state of the art commercial manufacturing site is prepared for scaled up and commercial grade production of radiolabeled drugs and isotopes (The Spica Center).

Our Mission

To improve patients life by providing innovative radiotheranostics and accelerating of discoveries in nuclear medicine

Management Team

Ebrahim S. Delpassand, MD

Founder & Chairman of the Board/ CEO of RadioMedix (2006)

• Board certified nuclear medicine physician 
• Former Deputy Chair and Chief of Clinical Nuclear Medicine MD. Anderson Cancer Center 
• Founder & Chariman of Excel Diagnostics & Nuclear Oncology Center (2003)  
• PI/Sponsor of current five INDs 
• Adjunct professor, Department of Radiation Oncology, UT and Nuclear Medicine at BCM in     
 • Co-Founder of Infinity Care (home healthcare company) and Infinity Infusion Care. 
• Executed exit strategy for acquisition of Infinity Infusion Care by Curative Healthcare in 2002.   

Izabela Tworowsska, Ph.D, MS.Pharm

Chief Scientific Officer

Co-Founder & Board Member

  • M.S.Pharm (Clinical), Medical University, Poland 
  • Ph.D. (Chemistry), Centre of Molecular and Macromolecular Studies, Polish Academy of Science 
  • J.W. Goethe Frankfurt University, Germany 
  •  William Rice Fellowship (Biochemistry), Rice University (Houston) 

• +25 years experience in the clinical pharmacy and chemistry 
• +13 years experience in oncology research 
• International awards: IUPAC and Sigma Aldrich Award 
• Expertise: CMC and pre-clinical evaluation of radiotheranostics drugs ( 4 INDs ) 
• Principal Investigator: 5 SBIR Phase I/II awards 
 • Co-author of +30 peer-review papers 
• Member NIH/NCI study section and Leader AlphaMedix project 

Ayda Delpassand, MSRS, MSGM  

Director of Quality Assuranceand Regulatory Affairs

  • MS (Regulatory Science) USC Los Angeles 
  • MS (Global Medicine), USC Los Angeles 
  • BS (Biology) SDSU San Diego

• Strategic and regulatory support of INDs and DMF 
• Strategic planning for CMC, Non-Clinical, Clinical, Pharmacology, Drug Safety, 
  Clinical Operations, Data Management, Biostatistics and Medical Writing to 
  support FDA submissions 
• Experienced in Regulatory Operations to ensure quality of submissions meet FDA standard 

David Ranganathan,PhD 

Director for CMC - Regulatory Affairs

  • M.Sc. (Chemistry) University of Madras (India) 
  • Ph.D. University of Camerino (Italy) 
  •  Postdoctoral fellowship Washington University School of Medicine                                    

• Extensive experience in translational oncology research, managing CMOs/CROs 
  and clinical drug development. 
• Authored CMC sections and managed regulatory support for 8 INDs and 1 NDA. 
• Managing a radiopharmaceutical manufacturing facility and also led multiple tech 
  transfer programs 
• Co-author scientific articles for peer-reviewed journals 

Alphard Orot, M.S 

Quality Assurance Manager  

  • MS Synthetic Organic Chemistry at Florida International University (Miami, FL)
  • BS Chemistry at University of San Carlos (Cebu, Philippines)                          

• Quality Manager with more than 20 years of experience working in cGMP compliant facilities. 
  Has a vast experience in implementing cGMP guidelines (21 CFR 210, 211, 212, ICH Q7) and 
  ISO standards (ISO 9001, ISO 14001).
• Extensive experience in writing SOPs and drafting CMCs for ANDAs and INDs.
• Extensive experience in aseptic manipulations following USP<71>, <51>, <61> and <62>.
• Strong background in Internal Auditing and Method Validation.